SAN DIEGO, CA - Halozyme Therapeutics , Inc. (NASDAQ:HALO), a biopharmaceutical company with a market capitalization of $7.4 billion, announced today that board member Connie L. Matsui has decided ...

Biotechnology pioneer Halozyme has developed ENHANZE, a drug delivery technology that can enable and optimize the subcutaneous (SC) drug delivery of coadministered therapeutics. ENHANZE is based ...

Helen Torley; President, Chief Executive Officer, Director; Halozyme Therapeutics Inc Nicole Labrosse; Chief Financial Officer, Senior Vice President; Halozyme Therapeutics Inc Good afternoon.

Halozyme delivered a record-breaking 2024, surpassing $1 billion in revenue and setting the stage for strong growth in 2025, driven by key products like DARZALEX subcutaneous and VYVGART Hytrulo.

Throughout the last three months, 9 analysts have evaluated Halozyme Therapeutics (NASDAQ:HALO), offering a diverse set of opinions from bullish to bearish. The following table summarizes their ...

Try Now>> See today’s best-performing stocks on TipRanks >> Read More on HALO: Halozyme Therapeutics NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

SAN DIEGO, Feb. 26, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, will present and host ...

At Halozyme Therapeutics Inc, recent insider activity has drawn attention. Over the last 30 days, insiders have reported selling a total of 26.70K shares worth $1.55M, meanwhile, insiders have ...

Halozyme Therapeutics issues guidance on future EPS and revenue, giving investors insight into how much the company expects to earn in upcoming periods. The most recent guidance for Halozyme ...

My name is Karen, and I will be your conference operator today. At this time, I would like to welcome everyone to the Halozyme Fourth Quarter and Full Year 2024 Financial and Operating Results ...